Hemophilia B epidemiology report 2030 gives a thorough understanding of the Hemophilia B by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. 

Hemophilia B Epidemiology Insight

DelveInsight’s ‘Hemophilia B - Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Hemophilia B epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.<h2>Geographies Covered</h2><ul><li>The United States</li><li>EU5 (Germany, France, Italy, Spain, and the United Kingdom)</li><li>Japan</li></ul>Study Period: 2018–2030<h2>Hemophilia B Understanding</h2>Hemophilia is defined as an inherited bleeding disorder in which the blood does not clot properly. This can lead to spontaneous bleeding as well as bleeding following injuries or surgery. It is caused by a gene defect that decides how factors VIII, IX, or XI are produced by the body. One of the Hemophilia type is Hemophilia B, also called factor IX (FIX) deficiency or Christmas disease, is a genetic disorder caused by missing or defective factor IX, a clotting protein. Although it is passed down from parents to children, about one-third of cases are caused by a spontaneous mutation, a change in a gene. Clotting factors are specialized proteins needed for blood clotting, the process by which blood seals a wound to stop bleeding and promote healing. The two main symptoms are bleeding for longer than normal, and bruising easily. With this disease, even a small bump to the head can be serious. Diagnosis of hemophilia B is made by investigating the patient’s personal history of bleeding, the patient’s family history of bleeding and inheritance, and laboratory testing. Several different specialized tests are necessary to confirm a diagnosis of hemophilia B. In order to determine if an individual has hemophilia B, specialized blood coagulation tests are used to measure how long it takes the blood to clot. The initial test is the activated partial thromboplastin time (aPTT). If the results of the aPTT test are abnormal, more specific blood tests must be used to determine if the cause of the abnormal aPTT is due to a deficiency of factor IX/hemophilia B, factor VIII/hemophilia A or another clotting factor. A specific factor assay also determines the severity level of the factor deficiency. Individuals with mild hemophilia have factor IX levels between 5 and 40% of normal; those with moderate hemophilia have factor levels from 1 to 5% of normal; and individuals with severe hemophilia have factor levels &lt;1% of normal.<h2>Epidemiology Perspective by DelveInsight</h2>The Hemophilia B epidemiology division provides the insights about historical and current Hemophilia B patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken. Key FindingsIn 2020, the overall prevalent cases of Hemophilia B accessed to be around&nbsp;10,739 in the 7MM, which are expected to grow during the study period, i.e., 2018–2030. The disease epidemiology covered in the report provides historical as well as forecasted Hemophilia B epidemiology [segmented as Total diagnosed Prevalent Pool of Hemophilia B, Severity-specific Prevalent Pool of Hemophilia B, Prevalent population of Hemophilia B with or without Inhibitors and Treated Prevalent Population of Hemophilia B] in the 7MM, covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2020 to 2030.<h2>Country Wise- Hemophilia B Epidemiology</h2><ul><li>In the United States, the total number of prevalent cases of Hemophilia B was 4,134 cases in the year 2020 which are expected to grow during the study period, i.e., 2018–2030.</li><li>In the year 2020, the total prevalent cases of Hemophilia B were 5,408 in EU-5, which are expected to grow during the study period, i.e., 2018–2030.</li><li>In Japan, the total number of prevalent cases of Hemophilia B was 1,198 in the year 2020 which are expected to grow during the study period, i.e., 2018–2030.</li><li>Moderate and severe accounts for ~75% of the Hemophilia B patient pool. In the 7MM, there were around&nbsp;8,054 moderate and severe Hemophilia B cases in 2020. </li><li>In the 7MM, approximately 5% of Hemophilia B cases develop inhibitors, i.e., 537 patients with inhibitors in 2020. In addition to this, 95% of the Hemophilia B cases were observed without inhibitors. The number of cases for both categories will increase during the study period.</li></ul><h2>Scope of the Report</h2><ul><li>The Hemophilia B report covers a detailed overview explaining its causes, symptoms, and pathophysiology, diagnosis, and treatment patterns.</li><li>The Hemophilia B Report and Model provide an overview of the risk factors and global trends of Hemophilia B in the seven major markets (7MM: United States, Germany, France, Italy, Spain, and the United Kingdom, and Japan)</li><li>The report provides insight about the historical and forecasted patient pool of Hemophilia B in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.</li><li>The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.</li><li>The report assesses the disease risk and burden and highlights the unmet needs of Hemophilia B.</li><li>The report provides the segmentation of the Hemophilia B epidemiology by diagnosed prevalent cases in the 7MM.</li><li>The report provides the segmentation of the Hemophilia B epidemiology by severity-specific cases of Hemophilia B in the 7MM.</li><li>The report provides the segmentation of the Hemophilia B epidemiology by with inhibitor and without inhibitor-specific cases B in the 7MM.</li><li>The report provides the segmentation of the Hemophilia B epidemiology by treated cases of in the 7MM.</li></ul><h2>Report Highlights</h2><ul><li>10-Year Forecast of Hemophilia B epidemiology</li><li>7MM Coverage </li><li>Total diagnosed Prevalent Pool of Hemophilia B</li><li>Severity-specific Prevalent Pool of Hemophilia B</li><li>Prevalent population of Hemophilia B with or without Inhibitors</li><li>Treated Prevalent Population of Hemophilia B</li></ul><h2>KOL-Views </h2>We interview, KOL’s and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the over Hemophilia B scenario of the indications.<h2>Key Questions Answered</h2><ul><li>What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Hemophilia B?</li><li>What are the key findings pertaining to the Hemophilia B epidemiology across the 7MM and which country will have the highest number of patients during the study period (2018–2030)?</li><li>What would be the total number of patients of Hemophilia B across the 7MM during the study period (2018–2030)?</li><li>Among the EU5 countries, which country will have the highest number of patients during the study period (2018–2030)?</li><li>At what CAGR the patient population is expected to grow in the 7MM during the study period (2018–2030)?</li><li>What are the various recent and upcoming events which are expected to improve the diagnosis of Hemophilia B?</li></ul><h2>Reasons to buy</h2>The Hemophilia B Epidemiology report will allow the user to -<ul><li>Develop business strategies by understanding the trends shaping and driving the global Hemophilia B market</li><li>Quantify patient populations in the global Hemophilia B market to improve product design, pricing, and launch plans</li><li>Organize sales and marketing efforts by identifying the age groups and gender that present the best opportunities for Hemophilia B therapeutics in each of the markets covered</li><li>Understand the magnitude of Hemophilia B population by its severity</li><li>The Hemophilia B epidemiology report and model were written and developed by Masters and PhD level epidemiologists</li><li>The Hemophilia B Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 10-year forecast period using reputable sources</li></ul><h2>Key Assessments</h2><ul><li>Patient Segmentation </li><li>Disease Risk and Burden</li><li>Risk of disease by the segmentation </li><li>Factors driving growth in a specific patient population</li></ul>

1. Key Insights2. Executive Summary of Hemophilia B3. Epidemiology an d Market Methodology4. Hemophilia B: Disease Background and Overview4.1. Classification of Hemophilia4.2. Sign and Symptoms of Hemophilia B4.3. The severity of Hemophilia B4.4. Risk factors and causes of Hemophilia B4.5. Pathophysiology4.6. Genetics of Hemophilia B4.7. Hemophilia and Inhibitors4.8. Diagnosis4.9. Diagnostic Algorithm4.10. Differential diagnosis of Hemophilia B4.11. Diagnostic Guidelines for Emergency Department Management of Individuals with Hemophilia and Other Bleeding Disorders4.12. World Federation of Hemophilia (WFH) Guidelines for Diagnosis of Hemophilia5. Epidemiology and Patient Population5.1. Epidemiology Key Findings5.2. Assumptions and Rationale: 7MM5.3. Epidemiology Scenario: 7MM5.3.1. Total Diagnosed Prevalent Population of Hemophilia B in the 7MM5.3.2. Severity- Specific Prevalent Population of Hemophilia B in the 7MM5.3.3. Prevalent population of Hemophilia B with or without Inhibitors the 7MM5.3.4. Treated Prevalent Population of Hemophilia B in the 7MM5.4. United States Epidemiology5.4.1. Total Diagnosed Prevalent Population of Hemophilia B in the United States5.4.2. Severity- Specific Prevalent Population of Hemophilia B in the United States5.4.3. Prevalent population of Hemophilia B with Inhibitors and Without Inhibitors in the United States5.4.4. Treated Prevalent Population of Hemophilia B in the United States5.5. EU-5 Country-wise Epidemiology5.5.1. Germany Epidemiology5.5.1.1. Total Diagnosed Prevalent Population of Hemophilia B in Germany5.5.1.2. Severity- Specific Prevalent Population of Hemophilia B in Germany5.5.1.3. Prevalent population of Hemophilia B with or without Inhibitors in Germany5.5.1.4. Treated Prevalent Population of Hemophilia B in Germany5.5.2. France Epidemiology5.5.2.1. Total Diagnosed Prevalent Population of Hemophilia B in France5.5.2.2. Severity- Specific Prevalent Population of Hemophilia B in France5.5.2.3. Prevalent population of Hemophilia B with or without Inhibitors in France5.5.2.4. Treated Prevalent Population of Hemophilia B in France5.5.3. Italy Epidemiology5.5.3.1. Total Diagnosed Prevalent Population of Hemophilia B in Italy5.5.3.2. Severity-Specific Prevalent Population of Hemophilia B in Italy5.5.3.3. Prevalent population of Hemophilia B with or without Inhibitors in Italy5.5.3.4. Treated Prevalent Population of Hemophilia B in Italy5.5.4. Spain Epidemiology5.5.4.1. Total Diagnosed Prevalent Population of Hemophilia B in Spain5.5.4.2. Severity- Specific Prevalent Population of Hemophilia B in Spain5.5.4.3. Prevalent population of Hemophilia B with or without Inhibitors in Spain5.5.4.4. Treated Prevalent Population of Hemophilia B in Spain5.5.5. United Kingdom Epidemiology5.5.5.1. Total Diagnosed Prevalent Population of Hemophilia B in the United Kingdom5.5.5.2. Severity-Specific Prevalent Population of Hemophilia B in the United Kingdom5.5.5.3. Prevalent population of Hemophilia B with or without Inhibitors in the United Kingdom5.5.5.4. Treated Prevalent Population of Hemophilia B in the United Kingdom5.6. Japan Epidemiology5.6.1. Total Diagnosed Prevalent Population of Hemophilia B in Japan5.6.2. Severity- Specific Prevalent Population of Hemophilia B in Japan5.6.3. Prevalence of Hemophilia B with Inhibitors and Without Inhibitors in Japan5.6.4. Treated Prevalent Population of Hemophilia B in Japan6. Appendix6.1. Bibliography6.2. Report Methodology7. DelveInsight Capabilities8. Disclaimer9. About DelveInsight

Hemophilia B - Epidemiology Forecast to 2030

DelveInsight's Hemophilia B - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Hemophilia B in the..